IMPORTANT - EIN Presswire is proud to announce the launch of its AI-powered press release generator. Try it now!

There were 2,798 press releases posted in the last 24 hours and 401,167 in the last 365 days.

NanoString Technologies Highlights Advances in Precision Oncology at the 58th Annual Meeting of the American Society of Hematology

Abstracts Demonstrate the Value of the nCounter Platform for Disease Characterization, Translational Research and Diagnostic Applications in Hematology

/EIN News/ -- SEATTLE, Nov. 30, 2016 (GLOBE NEWSWIRE) -- NanoString Technologies, Inc. (NASDAQ:NSTG), a provider of life science tools for translational research and molecular diagnostic products, today announced the highlights of numerous advances in precision oncology and hematology using the nCounter® platform that will be presented at the Annual Meeting of the American Society of Hematology (ASH).  

"We’re excited by the volume and impact of the important translational research that our customers and collaborators are presenting at the meeting of the American Society of Hematology," said Brad Gray, president and chief executive officer of NanoString Technologies. "This research includes significant advances in subtyping lymphomas and optimizing regimens to achieve better clinical outcomes."

The ASH Annual Meeting, being held December 3-6, in San Diego, will include at least seven oral presentations and nine posters that demonstrate the unique capabilities and robust performance of the nCounter platform.  In particular, several abstracts provide additional insights on the development and performance of NanoString’s assay in development for subtyping lymphoma.

In lymphoma, NanoString and its collaborators are presenting results generated using the nCounter-based Lymphoma Subtyping Test showing its analytical robustness and clinical relevance, including:

  • Analytical validation of the investigational nCounter®-based Lymphoma Subtyping Test for cell-of-origin (COO) identification in Formalin-Fixed Paraffin-Embedded (FFPE) Diffuse Large B-Cell Lymphoma (DLBCL) Specimens. The data show that this assay provides a highly precise, sensitive and rapid method for measuring COO on FFPE DLBCL tumor specimens, including both excisional and core needle biopsies. This assay is currently being used to select patients for a phase 3 clinical trial to evaluate lenalidomide plus R-CHOP versus placebo plus R-CHOP in patients who have newly diagnosed, previously untreated ABC-type DLBCL (Abstract #2933).

  • Data on outcomes by COO as determined via the investigational NanoString Lymphoma Subtyping Test on patients enrolled in a phase 2 study of lenalidomide combined with R-CHOP (R2CHOP) and an independent comparison cohort of patients treated with R-CHOP alone. The results show that R2CHOP demonstrates promising efficacy in ABC-type DLBCL as defined by the NanoString assay, where the addition of lenalidomide to R-CHOP appears to mitigate the negative prognostic impact of the ABC subtype in newly diagnosed DLBCL (Abstract #3035).

  • Results from an open-Label, randomized phase 3 study (GOYA) comparing the efficacy and safety of obinutuzumab plus CHOP (G-CHOP) with R-CHOP in patients with previously untreated DLBCL. A pre-specified secondary analysis of cell-of-origin by the investigational NanoString Lymphoma Subtyping Test showed a trend toward benefit from Gazyva in GCB-type DLBCL.  (Abstract #470).

  • Data on the first analysis of an international double-blind randomized phase 3 Study (REMARC) of lenalidomide maintenance in elderly patients with DLBCL treated with R-CHOP in first line, which include cell-of-origin analysis assessed by the NanoString Lymphoma Subtyping Test (Abstract #471).

The 2016 ASH abstracts describe research and clinical applications that underscore the diverse capabilities of the nCounter platform, which NanoString will showcase at booth #3651.

Abstract # Title Hyperlink
2933 Analytical Validation of the nCounter®-based Lymphoma Subtyping Test (LST) for Cell-of-Origin (COO) Identification in Formalin-Fixed Paraffin-Embedded (FFPE) Diffuse Large B-Cell Lymphoma (DLBCL) Specimens
3035 Lenalidomide Combined with R-CHOP (R2CHOP) Overcomes Negative Prognostic Impact of ABC Molecular Subtype in Newly Diagnosed Diffuse Large B-Cell Lymphoma
470 Obinutuzumab or Rituximab Plus CHOP in Patients with Previously Untreated Diffuse Large B-Cell Lymphoma: Final Results from an Open-Label, Randomized Phase 3 Study (GOYA)
471 First Analysis of an International Double-Blind Randomized Phase III Study of Lenalidomide Maintenance in Elderly Patients with DLBCL Treated with R-CHOP in First Line, the Remarc Study from Lysa
474 Lenalidomide Maintenance Significantly Improves Survival Figures in Patients with Relapsed Diffuse Large B-Cell Lymphoma (rDLBCL) Who Are Not Eligible for Autologous Stem Cell Transplantation (ASCT): Final Results of a Multicentre Phase II Trial
152 Integrating Genomic Alterations in Diffuse Large B-Cell Lymphoma Identifies New Relevant Pathways and Potential Therapeutic Targets
2935 Whole-Exome Analysis Reveals Novel Somatic Genomic Alterations Associated with Cell of Origin in Diffuse Large B-Cell Lymphoma
1107 Pembrolizumab in Relapsed/Refractory Classical Hodgkin Lymphoma: Primary End Point Analysis of the Phase 2 Keynote-087 Study
619 Phase 1b Study of Pembrolizumab in Patients with Relapsed/Refractory Primary Mediastinal Large B-Cell Lymphoma: Results from the Ongoing Keynote-013 Trial
918 A Novel Anti-Lymphoma Immune Evasion Mediated By the Interaction Between PD-1 Enriched NK-Cells and CD163+PD-L1+PD-L2+ Tumor Associated Macrophages, That Is More Prominent in Hodgkin Lymphoma Than Diffuse Large B-Cell Lymphoma
4576 Differential Expression of Immunity Related Genes and Early Prediction of Severe Graft Versus Host Disease after Allogeneic Hematopoietic Cell Transplantation
1954 Transcriptional Characterization of Myelofibrotic Bone Marrow Microenvironment Reveals Distinct Tumor Microenvironment in JAK2+ and Calr+ PMF Marrows
1664 Microvesicles microRNAs Reflect and Affect Progression of Acute Myeloid Leukemia and Could Serve As a Biomarker of Disease Dynamics
3285 Integrative Network Analysis of Newly Diagnosed Multiple Myeloma Identifies a Novel RNA-Seq Based High Risk gene Signature

About NanoString Technologies, Inc.
NanoString Technologies provides life science tools for translational research and molecular diagnostic products. The company's nCounter® Analysis System has been employed in life sciences research since it was first introduced in 2008 and has been cited in more than 1,350 peer-reviewed publications. The nCounter Analysis System offers a cost-effective way to easily profile the expression of hundreds of genes, proteins, miRNAs, or copy number variations, simultaneously with high sensitivity and precision, facilitating a wide variety of basic research and translational medicine applications, including biomarker discovery and validation. The company's technology is also being used in diagnostics. The Prosigna® Breast Cancer Prognostic Gene Signature Assay together with the nCounter Dx Analysis System is FDA 510(k) cleared for use as a prognostic indicator for distant recurrence of breast cancer. In addition, the company is collaborating with multiple biopharmaceutical companies in the development of companion diagnostic tests for various cancer therapies, helping to realize the promise of precision oncology.

For more information, please visit

The NanoString Technologies logo, NanoString, NanoString Technologies, nCounter and Prosigna are registered trademarks or trademarks of NanoString Technologies, Inc. in various jurisdictions.


Doug Farrell
Vice President, Investor Relations & Corporate Communications
Phone: 206-602-1768

Primary Logo